{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T08:41:46Z","timestamp":1771922506043,"version":"3.50.1"},"reference-count":53,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T00:00:00Z","timestamp":1768780800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Pregnancy-associated breast cancer (PrBC) poses complex challenges in diagnosis and treatment, particularly when associated with biologically aggressive subtypes and extensive nodal involvement. Management must be individualized, integrating oncologic urgency, fetal safety, and limited validated evidence in this unique setting.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case Summary<\/jats:title>\n                    <jats:p>We present the case of a 36-year-old woman diagnosed during the second trimester of pregnancy with HER2-positive (HER2+), node-positive (cT2[m]N3a) breast cancer (BC). After a multidisciplinary team discussion, patient initiated anthracycline- and taxane-based neoadjuvant chemotherapy during gestation. Given its contraindication during pregnancy, anti-HER2 therapy was added postpartum, and surgery included nipple-sparing mastectomy with targeted axillary dissection (TAD) of clipped nodes. Pathology revealed minimal residual invasive disease in the breast and a complete axillary response, allowing omission of axillary lymph node dissection (ALND). Genomic profiling with HER2DX supported high-risk disease and informed systemic therapy with delayed anti HER2 therapy, and conservative axillary management (TAD without ALND) in cT2N3 PrBC, without compromising fetal outcome. The patient subsequently received adjuvant chest wall and nodal region radiotherapy plus trastuzumab-emtansine (T-DM1).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This case underscores the value of personalized, multidisciplinary management in PrBC, particularly in patients with high-risk biologic features and advanced nodal disease. Integrating clinical judgment, genomic tools, and adaptive strategies, while accounting for gestational limitations, can optimize oncologic outcomes without compromising fetal safety.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2025.1672751","type":"journal-article","created":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T05:28:05Z","timestamp":1768800485000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Case Report: Personalized management of HER2-positive breast cancer with advanced nodal disease during pregnancy: a clinical case and review"],"prefix":"10.3389","volume":"15","author":[{"given":"Carla","family":"Gullotta","sequence":"first","affiliation":[{"name":"Translational Genomics and Targeted Therapies in Solid Tumors, August Pi i Sunyer Biomedical Research Institute (IDIBAPS)","place":["Barcelona, Spain"]},{"name":"Cancer Institute and Blood Diseases, Hospital Clinic de Barcelona","place":["Barcelona, Spain"]},{"name":"Department of Oncology, Fondazione Policlinico Universitario Campus Bio-Medico di Roma","place":["Rome, Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benjamin","family":"Walbaum","sequence":"additional","affiliation":[{"name":"Translational Genomics and Targeted Therapies in Solid Tumors, August Pi i Sunyer Biomedical Research Institute (IDIBAPS)","place":["Barcelona, Spain"]},{"name":"Cancer Institute and Blood Diseases, Hospital Clinic de Barcelona","place":["Barcelona, Spain"]},{"name":"Department of Hematology Oncology, Pontificia Universidad Cat\u00f3lica de Chile","place":["Santiago, Chile"]},{"name":"Faculty of Medicine, Pontificia Universidad Cat\u00f3lica de Chile","place":["Santiago, Chile"]},{"name":"Facultat de Medicina i Ciencias de la Salut, Universitat de Barcelona (UB)","place":["Barcelona, Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elia","family":"Segu\u00ed","sequence":"additional","affiliation":[{"name":"Translational Genomics and Targeted Therapies in Solid Tumors, August Pi i Sunyer Biomedical Research Institute (IDIBAPS)","place":["Barcelona, Spain"]},{"name":"Cancer Institute and Blood Diseases, Hospital Clinic de Barcelona","place":["Barcelona, Spain"]},{"name":"Facultat de Medicina i Ciencias de la Salut, Universitat de Barcelona (UB)","place":["Barcelona, Spain"]},{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute","place":["Boston, MA, United States"]},{"name":"Breast Oncology Program, Dana-Farber Cancer Institute","place":["Boston, MA, United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marta","family":"L\u00f3pez","sequence":"additional","affiliation":[{"name":"Facultat de Medicina i Ciencias de la Salut, Universitat de Barcelona (UB)","place":["Barcelona, Spain"]},{"name":"Department of Obstetrics and Gynecology and Neonatology, Hospital Clinic of Barcelona","place":["Barcelona, Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eduard","family":"Mension","sequence":"additional","affiliation":[{"name":"Translational Genomics and Targeted Therapies in Solid Tumors, August Pi i Sunyer Biomedical Research Institute (IDIBAPS)","place":["Barcelona, Spain"]},{"name":"Facultat de Medicina i Ciencias de la Salut, Universitat de Barcelona (UB)","place":["Barcelona, Spain"]},{"name":"Department of Obstetrics and Gynecology and Neonatology, Hospital Clinic of Barcelona","place":["Barcelona, Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isaac","family":"Cebrecos","sequence":"additional","affiliation":[{"name":"Facultat de Medicina i Ciencias de la Salut, Universitat de Barcelona (UB)","place":["Barcelona, Spain"]},{"name":"Department of Obstetrics and Gynecology and Neonatology, Hospital Clinic of Barcelona","place":["Barcelona, Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meritxell","family":"Molla","sequence":"additional","affiliation":[{"name":"Translational Genomics and Targeted Therapies in Solid Tumors, August Pi i Sunyer Biomedical Research Institute (IDIBAPS)","place":["Barcelona, Spain"]},{"name":"Facultat de Medicina i Ciencias de la Salut, Universitat de Barcelona (UB)","place":["Barcelona, Spain"]},{"name":"Radiation Oncology Department, Hospital Clinic Barcelona","place":["Barcelona, Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabriela","family":"Oses","sequence":"additional","affiliation":[{"name":"Facultat de Medicina i Ciencias de la Salut, Universitat de Barcelona (UB)","place":["Barcelona, Spain"]},{"name":"Radiation Oncology Department, Hospital Clinic Barcelona","place":["Barcelona, Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xavier","family":"Bargall\u00f3","sequence":"additional","affiliation":[{"name":"Facultat de Medicina i Ciencias de la Salut, Universitat de Barcelona (UB)","place":["Barcelona, Spain"]},{"name":"Department of Radiology, Hospital Clinic","place":["Barcelona, Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sergi","family":"Ganau-Macias","sequence":"additional","affiliation":[{"name":"Facultat de Medicina i Ciencias de la Salut, Universitat de Barcelona (UB)","place":["Barcelona, Spain"]},{"name":"Department of Radiology, Hospital Clinic","place":["Barcelona, Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Esther","family":"Sanfeliu","sequence":"additional","affiliation":[{"name":"Translational Genomics and Targeted Therapies in Solid Tumors, August Pi i Sunyer Biomedical Research Institute (IDIBAPS)","place":["Barcelona, Spain"]},{"name":"Facultat de Medicina i Ciencias de la Salut, Universitat de Barcelona (UB)","place":["Barcelona, Spain"]},{"name":"Pathology Department, Hospital Cl\u00ednic de Barcelona","place":["Barcelona, Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fara","family":"Braso-Maristany","sequence":"additional","affiliation":[{"name":"Translational Genomics and Targeted Therapies in Solid Tumors, August Pi i Sunyer Biomedical Research Institute (IDIBAPS)","place":["Barcelona, Spain"]},{"name":"Cancer Institute and Blood Diseases, Hospital Clinic de Barcelona","place":["Barcelona, Spain"]},{"name":"Molecular Biology CORE (CDB), Hospital Cl\u00ednic de Barcelona","place":["Barcelona, Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Montserrat","family":"Mu\u00f1oz","sequence":"additional","affiliation":[{"name":"Translational Genomics and Targeted Therapies in Solid Tumors, August Pi i Sunyer Biomedical Research Institute (IDIBAPS)","place":["Barcelona, Spain"]},{"name":"Cancer Institute and Blood Diseases, Hospital Clinic de Barcelona","place":["Barcelona, Spain"]},{"name":"Facultat de Medicina i Ciencias de la Salut, Universitat de Barcelona (UB)","place":["Barcelona, Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aleix","family":"Prat","sequence":"additional","affiliation":[{"name":"Translational Genomics and Targeted Therapies in Solid Tumors, August Pi i Sunyer Biomedical Research Institute (IDIBAPS)","place":["Barcelona, Spain"]},{"name":"Cancer Institute and Blood Diseases, Hospital Clinic de Barcelona","place":["Barcelona, Spain"]},{"name":"Facultat de Medicina i Ciencias de la Salut, Universitat de Barcelona (UB)","place":["Barcelona, Spain"]},{"name":"Reveal Genomics","place":["Barcelona, Spain"]},{"name":"Institute of Oncology (IOB), Hospital Quironsalud","place":["Barcelona, Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda","family":"Vidal","sequence":"additional","affiliation":[{"name":"Translational Genomics and Targeted Therapies in Solid Tumors, August Pi i Sunyer Biomedical Research Institute (IDIBAPS)","place":["Barcelona, Spain"]},{"name":"Cancer Institute and Blood Diseases, Hospital Clinic de Barcelona","place":["Barcelona, Spain"]},{"name":"Facultat de Medicina i Ciencias de la Salut, Universitat de Barcelona (UB)","place":["Barcelona, Spain"]},{"name":"Institute of Oncology (IOB), Hospital Quironsalud","place":["Barcelona, Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara","family":"Adamo","sequence":"additional","affiliation":[{"name":"Translational Genomics and Targeted Therapies in Solid Tumors, August Pi i Sunyer Biomedical Research Institute (IDIBAPS)","place":["Barcelona, Spain"]},{"name":"Cancer Institute and Blood Diseases, Hospital Clinic de Barcelona","place":["Barcelona, Spain"]},{"name":"Facultat de Medicina i Ciencias de la Salut, Universitat de Barcelona (UB)","place":["Barcelona, Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,1,19]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1097\/IGC.0000000000000904","article-title":"Frequency of pregnancy related cancer: A population based linkage study in lombardy, Italy","volume":"27","author":"Parazzini","year":"2017","journal-title":"Int J Gynecological Cancer"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1097\/AOG.0b013e3181b19154","article-title":"Increasing incidence of pregnancy-associated breast cancer in Sweden","volume":"114","author":"Andersson","year":"2009","journal-title":"Obstetrics Gynecology"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1097\/AOG.0b013e3182a057a2","article-title":"Incidence of pregnancy-associated cancer in Denmark, 1977\u20132006","volume":"122","author":"Eibye","year":"2013","journal-title":"Obstetrics Gynecology"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1111\/j.1471-0528.2012.03475.x","article-title":"Incidence and outcomes of pregnancy-associated cancer in Australia, 1994-2008: A population-based linkage study","volume":"119","author":"Lee","year":"2012","journal-title":"BJOG: Int J Obstetrics Gynaecology"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2021.39.15_suppl.515","article-title":"Outcome of breast cancer patients treated with chemotherapy during pregnancy compared with non-pregnant controls","volume":"39","author":"Amant","year":"2025","journal-title":"J Clin Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.45.6335","article-title":"Prognosis of women with primary breast cancer diagnosed during pregnancy: results from an international collaborative study","volume":"31","author":"Amant","year":"2013","journal-title":"J Clin Oncol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-020-06724-5","article-title":"Clinical features and survival of pregnancy-associated breast cancer: A retrospective study of 203 cases in China","volume":"20","author":"Han","year":"2020","journal-title":"BMC Cancer"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminoncol.2018.03.003","article-title":"Viable Pregnancy in a patient with metastatic melanoma treated with double checkpoint immunotherapy","volume":"45","author":"Burotto","year":"2018","journal-title":"Semin Oncol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/JGO.17.00019","article-title":"Case report of a pregnancy during ipilimumab therapy","volume":"2018","author":"Mehta","year":"2018","journal-title":"J Glob Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00525-8","article-title":"Immunotherapy for cancer treatment during pregnancy","volume":"22","author":"Borgers","year":"2021","journal-title":"Lancet Oncol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2015.03.001","article-title":"Targeted agents for cancer treatment during pregnancy","volume":"41","author":"Lambertini","year":"2015","journal-title":"Cancer Treat Rev"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1586\/eci.10.77","article-title":"Treatment of cancer during pregnancy with monoclonal antibodies: A real challenge","volume":"6","author":"Azim","year":"2010","journal-title":"Expert Rev Clin Immunol"},{"key":"B13","doi-asserted-by":"crossref","DOI":"10.1186\/s13244-022-01214-7","article-title":"Breast MRI during pregnancy and lactation: clinical challenges and technical advances","volume-title":"Insights into Imaging","author":"Nissan","year":"2022"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.2019182789","article-title":"Diffusion-weighted MRI for unenhanced breast cancer screening","volume":"293","author":"Amornsiripanitch","year":"2019","journal-title":"Radiology"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1007\/s00330-017-5126-z","article-title":"Feasibility of whole-body diffusion-weighted MRI for detection of primary tumour, nodal and distant metastases in women with cancer during pregnancy: a pilot study","volume":"28","author":"Han","year":"2018","journal-title":"Eur Radiol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.11.007","article-title":"Circulating tumor DNA in neoadjuvant-treated breast cancer reflects response and survival","volume":"32","author":"Magbanua","year":"2021","journal-title":"Ann Oncol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2024.103987","article-title":"HER2DX genomic test in early-stage HER2-positive breast cancer","volume":"9","author":"Tolaney","year":"2024","journal-title":"ESMO Open"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1814017","article-title":"Trastuzumab emtansine for residual invasive HER2-positive breast cancer","volume":"380","author":"von Minckwitz","year":"2019","journal-title":"New Engl J Med"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz173","article-title":"Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"30","author":"Cardoso","year":"2019","journal-title":"Ann Oncol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(12)70261-9","article-title":"Treatment of breast cancer during pregnancy: an observational study","volume":"13","author":"Loibl","year":"2012","journal-title":"Lancet Oncol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2024.0035","article-title":"Breast cancer, version 3.2024, NCCN clinical practice guidelines in oncology","volume":"22","author":"Gradishar","year":"2024","journal-title":"J Natl Compr Cancer Network"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/cancers13061238","article-title":"Cancer during pregnancy: A review of preclinical and clinical transplacental transfer of anticancer agents","volume":"13","author":"Benoit","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-012-1996-6","article-title":"Pregnancy occurring during or following adjuvant trastuzumab in patients enrolled in the HERA trial (BIG 01-01)","volume":"133","author":"Azim","year":"2012","journal-title":"Breast Cancer Res Treat"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1385\/CRIAI:26:3:161","article-title":"Immunology of pregnancy: implications for the mother","volume":"26","author":"Poole","year":"2004","journal-title":"Clin Rev Allergy Immunol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2015.00128","article-title":"HLA-G orchestrates the early interaction of human trophoblasts with the maternal niche","volume":"6","author":"Gregori","year":"2015","journal-title":"Front Immunol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(11)61092-1","article-title":"Breast cancer in pregnancy","volume":"379","author":"Amant","year":"2012","journal-title":"Lancet"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2308135","article-title":"Severe immune-related enteritis after in utero exposure to pembrolizumab","volume":"389","author":"Baarslag","year":"2023","journal-title":"New Engl J Med"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9378(96)70676-2","article-title":"Transplacental passage of recombinant human granulocyte colony-stimulating factor in women with an imminent preterm delivery","volume":"174","author":"Calhoun","year":"1996","journal-title":"Am J Obstet Gynecol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/cancers13061214","article-title":"Maternal and neonatal outcome after the use of g-csf for cancer treatment during pregnancy","volume":"13","author":"Berends","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1097\/aog.0b013e31826c32d9","article-title":"Maternal and neonatal outcomes of dose-dense chemotherapy for breast cancer in pregnancy","volume":"120","author":"Cardonick","year":"2012","journal-title":"Obstetrics Gynecology"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.4236\/jct.2012.32021","article-title":"The use of neupogen (Filgrastim) or neulasta (Pegfilgrastim) during pregnancy when chemotherapy is indicated for maternal cancer treatment","volume":"3","author":"Cardonick","year":"2012","journal-title":"J Cancer Ther"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.20f13472","article-title":"Major congenital malformation risk after first trimester gestational exposure to oral or intravenous ondansetron","volume":"81","author":"Andrade","year":"2020","journal-title":"J Clin Psychiatry"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1001\/jamapediatrics.2022.0483","article-title":"Evaluation of long-term outcomes associated with preterm exposure to antenatal corticosteroids: A systematic review and meta-analysis","volume":"176","author":"Ninan","year":"2022","journal-title":"JAMA Pediatrics. Am Med Association;"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1038\/tp.2017.65","article-title":"Antenatal dexamethasone exposure differentially affects distinct cortical neural progenitor cells and triggers long-term changes in murine cerebral architecture and behavior","volume":"7","author":"Tsiarli","year":"2017","journal-title":"Transl Psychiatry"},{"key":"B35","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.placenta.2005.12.010","article-title":"Metabolism of synthetic steroids by the human placenta","volume":"28","author":"Murphy","year":"2007","journal-title":"Placenta"},{"key":"B36","doi-asserted-by":"publisher","first-page":"103801","DOI":"10.1016\/j","article-title":"Development and validation of the new HER2DX assay for predicting pathological response and survival outcome in early-stage HER2-positive breast cancer","volume":"75","author":"Prat","year":"2022","journal-title":"EBioMedicine"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2023.05.012","article-title":"Association of HER2DX with pathological complete response and survival outcomes in HER2-positive breast cancer","volume":"34","author":"Villacampa","year":"2023","journal-title":"Ann Oncol"},{"key":"B38","doi-asserted-by":"publisher","first-page":"100123","DOI":"10.1016\/j.esmorw.2025.100123","article-title":"Clinical decision impact of HER2DX, an algorithm-powered genomic diagnostic in early-stage HER2-positive breast cancer: results from a prospective real-world study","volume":"8","author":"Mart\u00ednez-S\u00e1ez","year":"2025","journal-title":"ESMO Real World Data Digital Oncol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2024.102903","article-title":"Analytical validation of HER2DX genomic test for early-stage HER2-positive breast cancer","volume":"9","author":"Mar\u00edn-Aguilera","year":"2024","journal-title":"ESMO Open"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2023.0181","article-title":"Assessment of the HER2DX assay in patients with ERBB2 -positive breast cancer treated with neoadjuvant paclitaxel, trastuzumab, and pertuzumab","volume":"9","author":"Waks","year":"2023","journal-title":"JAMA Oncol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-11-2599","article-title":"Elucidating prognosis and biology of breast cancer arising in young women using gene expression profiling","volume":"18","author":"Azim","year":"2012","journal-title":"Clin Cancer Res"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1530\/ERC-14-0111","article-title":"Biology of breast cancer during pregnancy using genomic profiling","volume":"21","author":"Azim","year":"2014","journal-title":"Endocr Relat Cancer"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1116569","article-title":"Immune microenvironment dynamics in breast cancer during pregnancy: impact of gestational age on tumor-infiltrating lymphocytes and prognosis","volume":"13","author":"Sajjadi","year":"2023","journal-title":"Front Oncol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2024.104109","article-title":"Linking tumor immune infiltration to enhanced longevity in recurrence-free breast cancer","volume":"10","author":"Angelats","year":"2025","journal-title":"ESMO Open"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(24)00054-0","article-title":"3-year invasive disease-free survival with chemotherapy de-escalation using an 18F-FDG-PET-based, pathological complete response-adapted strategy in HER2-positive early breast cancer (PHERGain): a randomised, open-label, phase 2 trial","volume":"403","author":"P\u00e9rez-Garc\u00eda","year":"2024","journal-title":"Lancet"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(24)00104-9","article-title":"MRI-guided optimisation of neoadjuvant chemotherapy duration in stage II-III HER2-positive breast cancer (TRAIN-3): a multicentre, single-arm, phase 2 study","volume":"25","author":"van der Voort","year":"2024","journal-title":"Lancet Oncol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2401029","article-title":"Prenatal cfDNA sequencing and incidental detection of maternal cancer","volume":"391","author":"Turriff","year":"2024","journal-title":"New Engl J Med"},{"key":"B48","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.bpobgyn.2022.05.001","article-title":"Breast cancer during pregnancy: epidemiology, phenotypes, presentation during pregnancy and therapeutic modalities","volume":"82","author":"Boere","year":"2022","journal-title":"Best Pract Res Clin Obstet Gynaecol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1177\/17588359251369973","article-title":"Pregnancy and breast cancer in young women: current updates and future directions","volume":"17","author":"Zhang","year":"2025","journal-title":"Ther Adv Med Oncol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.64.0094","article-title":"Improved axillary evaluation following neoadjuvant therapy for patients with node-positive breast cancer using selective evaluation of clipped nodes: implementation of targeted axillary dissection","volume":"34","author":"Caudle","year":"2016","journal-title":"J Clin Oncol"},{"key":"B51","doi-asserted-by":"publisher","first-page":"104411","DOI":"10.1016\/j.breast.2025.104411","article-title":"Omitting axillary lymph node dissection in breast cancer patients with extensive nodal disease and excellent response to primary systemic therapy using the MARI protocol","volume":"80","author":"van Hemert","year":"2025","journal-title":"Breast"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-024-16630-w","article-title":"Outcomes and trends in axillary management of stage cN3b breast cancer patients","volume":"32","author":"Selfridge","year":"2025","journal-title":"Ann Surg Oncol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.sabcs23-gs02-07","article-title":"Loco-regional irradiation in patients with biopsy-proven axillary node involvement at presentation who become pathologically node-negative after neoadjuvant chemotherapy: primary outcomes of NRG oncology\/NSABP B-51\/RTOG 1304","author":"Mamounas","year":"2023"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1672751\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T07:36:23Z","timestamp":1771918583000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1672751\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,19]]},"references-count":53,"alternative-id":["10.3389\/fonc.2025.1672751"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2025.1672751","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,19]]},"article-number":"1672751"}}